Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148236 · ClinicalTrials.gov registry record · Phase 2
Vitamin C in Atrial Fibrillation Ablation
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03148236 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 20 participants.
The verdict
NCT03148236, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Single-center, double-blinded, randomized, controlled safety and feasibility pilot study of high dose IV ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered every six hours with a 30 minute IV infusion time per dose, compared to matched placebo infusion
Interventions
- OTHER Placebo
- DRUG Vitamin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2018-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148236
The ClinicalTrials.gov registry entry for NCT03148236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03148236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03148236 about?
NCT03148236 is a clinical study titled "Vitamin C in Atrial Fibrillation Ablation". Single-center, double-blinded, randomized, controlled safety and feasibility pilot study of high dose IV ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered every six hours with a 30 minute IV infusion time per dose, compared to matched placebo infusion
What is the current status of trial NCT03148236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-09-18. Estimated completion is 2018-03-13.
What interventions are being tested in trial NCT03148236?
The interventions under investigation include: Placebo (OTHER), Vitamin C (DRUG).
Who is sponsoring clinical trial NCT03148236?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.